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Poster Session II S265allogenic or autologous BMT at Sydney Children’s Hospital, Aus-
tralia between February 2002 and December 2004.
Results: 20% of the patients were at risk of malnutrition on ad-
mission. All patients received parenteral nutrition (PN) as their
standard nutritional therapy, which was commenced on a mean
of day + 1 and was infused for an average of 26 days. Our patients
received an average of 79%610.6(40-100%) of estimated energy
requirements from PN. The glucose/amino acid infusion was in-
adequate on 40% of PN days with the main reason due to fluid
overload causing a reduction in infusion rates. The lipid infusion
was inadequate on 60% of PN days mainly due to stoppages
when drugs and/or blood products were infused. The mean per-
centage weight change on discharge was +0.36 4.7%. This had
a large range of between –9.9% to + 7.9% of body weight and
did not appear to relate to adequacy of parenteral nutrition during
transplant. We found that those patients who had weight loss on
discharge had greater number of days off PN prior to discharge
than those with no weight loss. Those patients who received
enteral nutrition (21%) prior to discharge had no weight loss on
discharge.
Conclusion: This study showed that although frequent rate reduc-
tions in nutrition infusions did occur due to fluid overload or drug
incompatibility with PN, patients still received the majority of their
nutritional requirements. Weight loss on discharge from transplant
may be more indicative of the adequacy of oral/enteral nutrition
prior to discharge rather than the adequacy of the nutrition support
during the transplant. Long-term consequences of inadequate nutri-
tion during a BMT as well as nutritional issues post BMT requires
further study.
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H1N1 INFECTION IN STEM CELL TRANSPLANT PATIENTS
Gupta, S.1, Bayer, R.-L.2 1 Nalitt Institute of Cancer and Blood Related
Disorders, Staten Island University Hospital, NY; 2 Monter Cancer Cen-
ter, North Shore-Long Island Jewish Health System, NY
Influenza A virus can be a significant cause of morbidity and mor-
tality in the general population as well as in immunocompromised
patients.
We present instances where stem cell transplant patients devel-
oped H1N1 infection with encouraging outcomes.
Case 1: A 26 year old male with history of relapsed Hodgkin’s dis-
ease status post autologous peripheral blood stem cell transplant in
December 2008, presented with fever and cough six months after
transplantation. His chest X-ray revealed consolidation and CT
scan of the chest showed ground glass opacities throughout the
lungs. The patient was started on intravenous antibiotics and a respi-
ratory panel was sent. The panel was positive for non-typeable influ-
enza A, indicative of H1N1 infection. The antibiotics were stopped
and Oseltamavir was initiated. After 5 days of treatment, the patient’s
symptoms resolved, and his repeat CT scan showed marked resolu-
tion of the ground glass opacities.
Case 2: A 64 year old male patient with history of relapsed, trans-
formed low grade lymphoma, status post unrelated reduced intensity
allogeneic bone marrow transplantation in December 2008, compli-
cated by GVHD, presented in May 2009, with new onset throat dis-
comfort, cough and fever. A respiratory panel was positive for non-
typeable influenza A and CT scan of the chest revealed bilateral
lung consolidation. The patient was started on Oseltamavir, with
complete resolution of symptoms and improved CT findings.
Discussion: In March 2009, the pandemic caused by H1N1 influ-
enza claimed thousands of lives. This strain of virus represents a qua-
druple reassortment of two swine strains, one human strain and one
avian strain.
Although real time PCR is the most sensitive and specific test for
the diagnosis of H1N1, recent CDC guidelines, do not recommend
this test for every presumed case of H1N1 infection. During the
spring of 2009, a diagnosis of H1N1 infection could be made, if a pa-
tient presented with signs and symptoms of upper or lower respira-
tory tract involvement and if influenza A was identified on
a respiratory panel. Our patients were diagnosed with H1N1 infec-
tion and with the use of Oseltamavir, had complete response and res-
olution of symptoms with minimal morbidity.
Thus we conclude that H1N1 infection may not be associated with
significant morbidity and mortality in stem cell transplant patients if
a timely diagnosis is made and treatment is initiated.290
RED CELL CONTENT IN PERIPHERAL HEMATOPOIETIC PROGENITOR
CELL (HPCA) COLLECTIONS FOR TRANSPLANT IN PEDIATRIC PATIENTS.
COMPARISON TO ADULT MATCHED UNRELATED (URD) PERIPHERAL
BLOOD COLLECTIONS. TO DETERMINE THE MAXIMUM ACCEPTABLE
VOLUME OF RED CELLS FOR INFUSION
Villa, M.1, Schneiderman, J.2, Duerst, R.2, Shook, T.1, Collins, J.3,
Meagher, R.1, Kletzel, M.2 1 Northwestern Memorial Hospital, Chicago,
IL; 2 Northwestern University Feinberg School of Medicine, Chicago, IL;
3 Children’s Memorial Hospital, Chicago, IL
We assessed the amount of red cells in peripheral blood collec-
tions from pediatric patients and compare them to adult URD col-
lections.
Twelve pediatric HPCA collections (5 allo and 7 auto) using the
BCT Spectra at Children’s Memorial Hospital were compared to
18 URD collections from multiple institutions received at North-
western Memorial Hospital Cellular Processing Facility (CTPF)
from January to July 2009. Column statistics and t test were per-
formed on Prism software.
The median total product volume collected per harvest of the
URD was 293 ml (range 166-447) mean 299 SEM + 18 (95% CI
261-337) The median total product volume collected from pediatric
donors was 133 (range 16-299) mean 138 SEM + 29 (95% CI 75-202)
p\0.0001. The median Hct per collection of the URD was 6.5%
(range 3-17) mean 7.6 SEM +0.8 (95% CI 5.8-9.3) and from the pe-
diatric collections, the median Hct was 9.5% (range 4.0-19) mean 9.6
SEM + 1.4 (95% CI 6.3-2.7) p5 0.99. The median red cell volume
per collection for the URDs was 24 ml (range 9-46) mean 23
SEM + 2.3 (95% CI 18-28) while for the pediatric donors, the me-
dian was 8.5 ml (range 4-36) mean 12 SEM +2.4 (95% CI 6.1-
17.0) p5 0.003.
The Hct in URD vs. pediatric collections was not statistically sig-
nificantly different. Since the red cell content is dependent on the to-
tal product volume, the red cell volume was greater in the URD
collections. HPCA infusions.CRA – DATA MANAGEMENT
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CLINICAL IMPACT OF STOMATITIS SEVERE IN PATIENTS RECEIVING
MYELOBLATIVE, NON MYELOABLATIVE AND REDUCED INTENSITY CON-
DITIONING REGIMENS AND HAEMATOPOIETIC PROGENITOR TRANS-
PLANTATION: EXPERIENCE OF SINGLE CENTER
Gomez-Morales, E.1, Azucena, S.-G.2 1 ABC Medical Center, Mexico;
2 ABC Medical Center, Mexico
Introduction: Stomatitis severe is the mayor limiting dose by pre-
parative regimen in stem cell transplantation reporting percentages
that vary widely (0% to 100%) associated with intensity chemother-
apy but these percentages not are real (0% with minimal intensity
and 100% with myeloablative regimen) and this represent the goal
of this study additional to analyze their clinical impact on another
complications in transplantation field.
Patients and Methods: Observational and transversal study was
made in patients receiving stem cell transplantation since November
2002 to September 2009 in ABC Medical Center Mexico City. All
were older 1 year (female or male). The preparative regimen were
separated into myeloablative, non myeloablative (or moderate-inten-
sity) and minimal-intensity in relation with CIBMTR criteria. The
presence of erytema, edema, pain, sore throat and ulcerations mouth
after chemotherapy was defined stomatitis and their severity was
graduated with NCTC v3.0 scale (Stomatitis grade 3 y 4 was defined
severe).
Results: 52 patients with medium age 29 years old (range 2-72).
Predominance male (56.6%; ratio M:F 1.4:1). 21 patients received
myeloablative regimen (40.5%), 19 non myeloablative (36.5%) y
12 minimal-intensity (23%). 23 patients presented stomatitis se-
vere (44.23%) predominance in myeloablative regimens (56.52%
vs 30.4% non myeloablative y 13% minimal intensity) and alloge-
neic transplantation (60.86%). 65.2% of cases with stomatitis
grade 3 required opiates infusion and 100% total parenteral nu-
trition (independently preparative regimen). The febrile
S266 Poster Session IIneutropenia incidence increase with regimen dose intensity
(52.38% for myeloablative, 36.8% non myeloablative and 25%
with minimal intensity). The stomatitis severe mortality is 26%
in our study group (100% by multiple organic failures without
difference between preparative regimens: 9.5% in myeloablative,
10.5% non myeloablative and 8.3% with minimal intensity)
into 50 days after transplantation and it delay hospital outpatient
day (29.3 vs 22.3 days). These parameters not impact on myeloid
graft day between vary regimens (14.3 vs 14 days) that represent
stomatitis resolution.
Conclusions: Preparative regimen with more intensity represent
more stomatitis severity in addition to increase adverse effects (fe-
brile neutropenia, opiate infusions use and total parenteral nutri-
tion) that represent another complications although they don’t
have impact on myeloid graft day and mortality by process.292
CASE STUDY: ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANTA-
TION (HSCT) FROM POINT OF VIEW OF THE PATIENT, THE DATA MAN-
AGER AND THE PHYSICIANS
Larsen, H.B.1,2, Roepstorff, C.1, Petersen, H.1, Sengeløv, H.1,
Heilmann, C.J.2 1 Rigshospitalet, Copenhagen, Denmark; 2 Rigshospitalet,
Copenhagen, Denmark
Introduction: Being a data manager in a HSCT-unit implies to cap-
tur accurate data from the patients medical record regarding the pa-
tients condition and complications.
Aim: The aim of this case study is to analyse the patient’s (pt) com-
plications from different view point[pos]s and to question if we cap-
ture all relevant information and from whose perspective.
Patient and Methods: We have selected a single pt. and performed
an in-dept interview to illustrate the different perspectives regarding
the patient’s complications.
The pt. is female (d.o.b 1978) diagnosed with Fanconi anemia in
1987, who developed MDS (RA) in 1999 and who were not treated
with chemotherapy before HSCT. Conditioning: CTX 10 mg/kg
in 4 days, Bu p.o. 0,375 mg/kg times 4 in 4 days. GvHD profylaxis:
CyA and MTX. She was transplanted with a matched sibling donor
in 2001. After the HSCT she faced a number of complications and
died as a result of these in 2009.
Results: See table 1.
Conclusion: Data Collection capture most of the pt.’s medical com-
plications and the physicians treatment of these, however the psy-
chosocial related issues also have a major impact on the pt.’s
quality of life, but these issues are not documented in any detail.Results
Data Managers report Physicians persp
Acute GvHD:2001 Grade III, (Skin stage III,
Gut stage II, Liver stage III)
CyA, Systemic steroids
Chronic GvHD: 2001 Extensive, Mild
(onset) developed to severe, Oral cavity:
Lichinoid changes, Ulcers, Liver:
Increased enzymes, Vagina: Agglutination,
dryness, Eyes: Dryness, conjunctivitis,
coronal erosions,
CyA, Steroids, MMF, Traco
2004, 2008, 2009 Corne
transplantations
Secondary cancer: 2002: Tongue
(Planocellulary carcinoma), 2006: Vulva
(Planocellulary carcinoma), 2008: Eye
(Squamous carcinoma), 2009: Cervix
Cancer stage II A
Removal of tumor, Remova
labia minor and major, R
eye, Hysterectomia with
Other Complications: 2003 and 2007:
Aseptic Bone Necrosis in hip, 2004:
Aseptic Bone Necrosis in knee, 2006:
Depression, 2006, 2008: Suicide Attempt
(pills)
Hip replacement of both hi
replacement, Medical tre
depressionThe pt.’s psychosocial well-being is often discussed and requires at-
tention, but are not systematically gathered in data collection. The
lack of a systematical collection of psychosocial information may
have an impact on the research questions asked within the field of al-
logeneic HSCT, so research related to the psychosocial perspective
do not revieve the same systematical and world wide attention.293
INDICATIONS AND OUTCOME OF STEM CELL TRANSPLANT AT THE AGA
KHAN UNIVERSITY HOSPITAL
Ali, N., Adil, S., Shaikh, U., Naz, N., Masood, N. The Aga Khan Uni-
versity Hospital
Objective:To determine indications, morbidity and mortality of Al-
logeneic and Autologous stem cell transplant.
Subjects andMethods: All patients who presented in bone marrow
transplant clinic with a potentially curable disease were included in
the study. Pre-transplant workup of the patient and donor included
a complete blood count, evaluation of liver, kidney, lung, infectious
profile, chest and paranasal sinus roentgenograms and dental review.
Mobilization was done with G-CSF 300mcg twice daily. The condi-
tioning regimens included Busulfan/Cyclophosphamide, Cyclo-
phosphamide/ATG/Fludarabine. BEAM, ICE and high dose
Melphalan. Chimerism studies were done by fluorescent in situ hy-
bridization (FISH) and variable non tandem repeats (VNTR) tech-
niques.
Results: A total of 98 transplants were done from April 2004 – Feb-
ruary 2009. Out of these n5 58 were allogeneic bone marrow trans-
plants whereas n5 40 were autologous transplant. There were
n5 73 males and n5 25 females. n5 35 were in the pediatric age
group (\15 years) while n5 63 were adults (.15 years). The main
indications for Allogeneic stem cell transplant were Aplastic Anemia
(n5 20) followed by Thalassemia Major (n5 16). For the autolo-
gous transplant, Non-Hodgkin’s Lymphoma was the most common
indication (n5 14) followed by Hodgkin’s disease (n5 9). Trans-
plant related mortality was 11.3% and 20.6% in Allogeneic and Au-
tologous procedures respectively. Causes of mortality included grade
IV GvHD, fungal infections, acute appendicitis and pneumonia.
Conclusion: A total of 98 stem cell transplants were done. The
transplant related mortality was higher in autologous transplant.
Common indications included Thalassemia Major, Aplastic Anemia
and Non Hodgkin’s Lymphoma.ective Patient experience
Prolonged hospitalisation, side effects from
medicine
limus, Sirolimus
a
Weight loss (diarrheoa, loss of appetite), Pain
and bleeding from vagina, dilataion of vagina
daily, loss of sexual pleaure. Loss of vision,
pain, everyday life as blind
l of clitoris and
emoval of one
B.S.O.
Fear of death, Loss of sexual pleasure, Loss of
vision of one eye, Loss of fertility
ps, Knee
atment for
Loss of physical function in a periode,
Psychotherapy, Feeling stigmatised, Psycho-
social relations: Loss of education, Loss of
work, Loss of spouse, friends, and strain on
family relations, Live with handicaps
